Attovia Therapeutics (NASDAQ:ATTO) reported quarterly losses of $(4.88) per share which missed the analyst consensus estimate of $(4.62) by 5.63 percent. This is a 31.54 percent decrease over losses of $(3.71) per share from the same period last year. The company reported $450.000 thousand in sales this quarter.